TNBC, defined by a lack of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptors, accounts for 15% to 20% of all breast cancers and typically has a poor prognosis (16). This evidence concerns the gene ERBB2 and breast carcinoma.